Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial | Zendy

Ron Wald | Zendy; Christian G. Rabbat | Zendy; Louis Girard | Zendy; Amit X. Garg | Zendy; Karthik Tennankore | Zendy; Jessica Tyrwhitt | Zendy; Andrew Smyth | Zendy; Andrea Rathe-Skafel | Zendy; Peggy Gao | Zendy; Andrea Mazzetti | Zendy; Jackie Bosch | Zendy; Andrew T. Yan | Zendy; Patrick S. Parfrey | Zendy; Braden Manns | Zendy; Michael Walsh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial

Author(s) -

Ron Wald,

Christian G. Rabbat,

Louis Girard,

Amit X. Garg,

Karthik Tennankore,

Jessica Tyrwhitt,

Andrew Smyth,

Andrea Rathe-Skafel,

Peggy Gao,

Andrea Mazzetti,

Jackie Bosch,

Andrew T. Yan,

Patrick S. Parfrey,

Braden Manns,

Michael Walsh

Publication year - 2017

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.10941016

Subject(s) - medicine , hyperphosphatemia , interquartile range , randomized controlled trial , phosphate binder , randomization , hemodialysis , confidence interval , phosphate , dialysis , clinical endpoint , lanthanum carbonate , gastroenterology , kidney disease , surgery , biochemistry , chemistry

Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events. A large randomized trial is needed to determine whether lowering phosphate concentrations with binders improves patient-important outcomes. To inform such an effort we conducted a pilot randomized controlled trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research